ENDRA Life Sciences Inc.
NDRA
$3.86
$0.29188.19%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -52.24% | -5.01% | 12.34% | -46.77% | -5.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.78% | -25.50% | -5.40% | -56.00% | -8.43% |
| Operating Income | 51.78% | 25.50% | 5.40% | 56.00% | 8.43% |
| Income Before Tax | 24.08% | 12.82% | 5.68% | 55.63% | 9.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.08% | 12.82% | 5.68% | 55.63% | 9.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.08% | 12.82% | 5.68% | 55.63% | 9.87% |
| EBIT | 51.78% | 25.50% | 5.40% | 56.00% | 8.43% |
| EBITDA | 51.65% | 24.91% | 4.81% | 56.24% | 8.73% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
